The advent of immune checkpoint inhibitors (ICIs) has revolutionized cancer therapy, offering improved survival outcomes in various malignancies. However, their use is associated with immune-related adverse events (irAEs), including severe cardiovascular compl... ...

请注册登录后继续浏览